Should GLP-1 receptor agonists be stopped a week before an endoscopy?

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional study examines whether stopping GLP-1 receptor agonists for seven days before an esophagogastroduodenoscopy leads to better gastric preparation and fewer repeat procedures. Eligible participants are adults aged 18–70 on stable GLP-1 therapies who are scheduled for EGD and meet certain health criteria. Participants are assigned to either discontinue GLP-1 therapy for one week or continue it, with monitoring around the endoscopy procedure. The trial aims to provide a clear, evidence-based pre-procedural recommendation for GLP-1 RA management prior to EGD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week).

  * Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose.
  * Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication.
  * Age between 18 and 70 years.
  * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  * Provision of written informed consent.
  * Outpatient status.
  * If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD.

Exclusion Criteria:

* • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis).

  * History of prior upper gastrointestinal resection (stomach, intestine, or esophagus).
  * Any other condition deemed inappropriate by the treating physician.
  * Body mass index (BMI) \> 40 kg/m².
  * Liver cirrhosis.
  * Parkinson's disease.
  * Dementia.
  * Use of tricyclic antidepressants or opioid medications for more than 3 months.

Where it's running

• Fjuh
  New Taipei City, Taiwan, Taiwan Recruiting

Study contacts

• Study coordinator: Kuan I Sung
• Email: ioudanny520@hotmail.com
• Phone: +886928139643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ubiquinol to See if It Reduces Fatigue for Adults Using GLP-1 Weight-Loss Meds

  A daily ubiquinol supplement is tested to see if it lowers fatigue and helps keep muscle strength in adults taking GLP-1 weight-loss medicines.

  Recruiting StudySetGo · Glasgow · NCT07789106

• Discontinuation timing of GLP-1 receptor agonists before colonoscopy

  This study tests whether stopping GLP-1 receptor agonists for either 0 or 7 days before colonoscopy affects bowel prep quality and the need for a repeat procedure in adults undergoing colonoscopy.

  Recruiting Fu Jen Catholic University Hospital · New Taipei, Taiwan · NCT07736963

• GLP-1 receptor agonists and dry eye in adults with type 2 diabetes and obesity

  This study tests whether GLP-1 receptor agonists affect dry eye disease in adults with type 2 diabetes and obesity.

  Recruiting Attikon Hospital · Athens · NCT07605572

• Lifestyle change program with GLP-1 medication users

  This trial tests whether the Noom digital lifestyle program helps adults on GLP-1 medications improve eating, activity, and weight-related health.

  Recruiting University of Massachusetts, Worcester · Worcester, Massachusetts · NCT07481305

• A nutritional supplement to fill nutrient gaps and support gut health for people taking GLP-1 medications.

  This study will test whether a daily nutritional supplement can reduce nutrient gaps and improve the gut microbiome in adults who are using GLP-1 receptor agonist medications.

  Recruiting Athletic Greens International · Santa Monica, California · NCT07437911

• Semaglutide's effects on heart and muscle mass

  This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07272837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.